US equities
|
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
NVDA
$216.00
▲+2.39%
META
$630.56
▼-1.88%
SPCX
$146.90
▼-0.40%
AAPL
$343.91
▼-1.10%
MSFT
$532.60
▲+1.54%
INTC
$90.47
▲+4.04%
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
NVDA
$216.00
▲+2.39%
META
$630.56
▼-1.88%
SPCX
$146.90
▼-0.40%
AAPL
$343.91
▼-1.10%
MSFT
$532.60
▲+1.54%
INTC
$90.47
▲+4.04%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Lexicon Pharmaceuticals, Inc. - Common Stock
(NQ:
LXRX
)
1.450
+0.030 (+2.11%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lexicon Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
Next >
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
October 23, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
October 21, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
September 01, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
August 31, 2026
Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
August 24, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
August 06, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
July 30, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
July 27, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
June 03, 2026
Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
May 28, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
May 12, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
May 07, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
May 04, 2026
$55 million funded at closing to repay existing loan facility
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
April 30, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
April 17, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
March 24, 2026
Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
March 23, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
March 11, 2026
Post hoc data analysis concluded that sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, improved glycemic control after one year in patients with normal and mildly reduced kidney function
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
March 05, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
March 03, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
February 26, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
February 06, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
January 30, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Announces Proposed Public Offering of Common Stock
January 29, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
January 23, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
January 21, 2026
– No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo –
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
January 09, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 07, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
December 10, 2025
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
